0000911916-17-000086.txt : 20170301
0000911916-17-000086.hdr.sgml : 20170301
20170301153449
ACCESSION NUMBER: 0000911916-17-000086
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170301
FILED AS OF DATE: 20170301
DATE AS OF CHANGE: 20170301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CoLucid Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001348649
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 203419541
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 781-365-2596
MAIL ADDRESS:
STREET 1: 222 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Colucid Pharmaceuticals Inc
DATE OF NAME CHANGE: 20060104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAPPAS CAPITAL, LLC
CENTRAL INDEX KEY: 0001320654
STATE OF INCORPORATION: NC
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37358
FILM NUMBER: 17653779
BUSINESS ADDRESS:
STREET 1: POST OFFICE BOX 110287
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
BUSINESS PHONE: (919) 998-3300
MAIL ADDRESS:
STREET 1: POST OFFICE BOX 110287
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 27709
FORMER NAME:
FORMER CONFORMED NAME: A.M. Pappas & Associates, LLC
DATE OF NAME CHANGE: 20050315
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PV III CEO Fund, L.P.
CENTRAL INDEX KEY: 0001573873
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37358
FILM NUMBER: 17653780
BUSINESS ADDRESS:
STREET 1: C/O PAPPAS VENTURES
STREET 2: PO BOX 110287
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 277709
BUSINESS PHONE: 919-998-3330
MAIL ADDRESS:
STREET 1: C/O PAPPAS VENTURES
STREET 2: PO BOX 110287
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 277709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: A.M. Pappas Life Science Ventures III, L.P.
CENTRAL INDEX KEY: 0001573854
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37358
FILM NUMBER: 17653781
BUSINESS ADDRESS:
STREET 1: C/O PAPPAS VENTURES
STREET 2: PO BOX 110287
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 277709
BUSINESS PHONE: 919-998-3330
MAIL ADDRESS:
STREET 1: C/O PAPPAS VENTURES
STREET 2: PO BOX 110287
CITY: RESEARCH TRIANGLE PARK
STATE: NC
ZIP: 277709
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PAPPAS ARTHUR M
CENTRAL INDEX KEY: 0001189543
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37358
FILM NUMBER: 17653782
MAIL ADDRESS:
STREET 1: 8995 WESTSIDE PARKWAY
CITY: ALPHARETTA
STATE: 2Q
ZIP: 30004
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2017-03-01
1
0001348649
CoLucid Pharmaceuticals, Inc.
CLCD
0001189543
PAPPAS ARTHUR M
C/O COLUCID PHARMACEUTICALS, INC.
222 THIRD STREET
CAMBRIDGE
MA
02142
1
0
1
0
0001573854
A.M. Pappas Life Science Ventures III, L.P.
2520 MERIDIAN PARKWAY, SUITE 400
DURHAM
NC
27713
0
0
1
0
0001573873
PV III CEO Fund, L.P.
2520 MERIDIAN PARKWAY, SUITE 400
DURHAM
NC
27713
0
0
1
0
0001320654
PAPPAS CAPITAL, LLC
2520 MERIDIAN PARKWAY, SUITE 400
DURHAM
NC
27713
0
0
1
0
Common Stock
2017-03-01
4
U
0
1871049
46.50
D
0
I
By A. M. Pappas Life Science Ventures III, L.P.
Common Stock
2017-03-01
4
U
0
116317
46.50
D
0
I
By PV III CEO Fund, L.P.
Common Stock
2017-03-01
4
U
0
5528
46.50
D
0
I
By Pappas Capital, LLC
Stock Option (Right to Buy)
10.00
2017-03-01
4
D
0
5954
36.50
D
2025-05-05
Common Stock
5954
0
D
Stock Option (Right to Buy)
6.24
2017-03-01
4
D
0
8897
40.26
D
2026-05-10
Common Stock
8897
0
D
Pursuant to the terms of the Agreement and Plan of Merger, dated January 17, 2017 (the "Merger Agreement"), by and among CoLucid Pharmaceuticals, Inc. (the "Issuer"), Eli Lilly and Company ("Lilly") and ProCar Acquisition Corporation, a wholly-owned subsidiary of Lilly, these shares were tendered pursuant to the Merger Agreement in exchange for a cash payment of $46.50 per share in cash, without interest.
Represents securities held directly by A.M. Pappas Life Science Ventures III, L.P. AMP&A Management III, LLC is the general partner of A. M. Pappas Life Science Ventures III, L.P. and has a management agreement with Pappas Capital, LLC (fka A. M. Pappas & Associates, LLC) ("Pappas Capital"). As a result, Pappas Capital's investment committee has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, all shares owned A.M. Pappas Life Science Ventures III, L.P. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Represents securities held directly by PV III CEO Fund, L.P. AMP&A Management III, LLC is the general partner of PV III CEO Fund, L.P. and has a management agreement with Pappas Capital. As a result, Pappas Capital's investment committee has sole power to vote or to direct the vote of, and sole power to dispose or to direct the disposition of, all shares owned PV III CEO Fund, L.P. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Represents securities held directly by Pappas Capital. The reporting person is the sole managing member of Pappas Capital. The reporting person may be deemed to be an indirect beneficial owner of the reported securities. The reporting person disclaims any beneficial ownership of the reported securities, except to the extent of any pecuniary interest therein. This report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Pursuant to the terms of the Merger Agreement, these options, which were fully vested, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
Pursuant to the terms of the Merger Agreement, these options, which provided for full vesting immediately prior to the start of the Issuer's first annual meeting of stockholders following the date of grant, were cancelled in exchange for a cash payment of $46.50 less the per share exercise price multiplied by the number of unexercised options, without interest.
/s/ Christine G. Long, Attorney-in-Fact for Arthur M. Pappas (power of attorney previously filed)
2017-03-01
/s/ Christine G. Long, Attorney-in-Fact for A.M. Pappas Life Science Ventures III, L.P. (power of attorney previously filed)
2017-03-01
/s/ Christine G. Long, Attorney-in-Fact for PV III CEO Fund, L.P. (power of attorney previously filed)
2017-03-01
/s/ Christine G. Long, Attorney-in-Fact for Pappas Capital, LLC (power of attorney previously filed)
2017-03-01